NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the signing of an extended collaborative research and development agreement with Pfizer Inc aimed at the discovery and development of vaccines to protect animals. The collaboration will employ vaccine technologies owned by AVANT.
